drugset / Trial / NCT00823212

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

NCT00823212 ↗

Phase 3 Completed 1530 enrolled Boston Scientific Corporation
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions. This clinical trial compares outcomes in patients treated with PROMUS Element to those in patients treated with a different everolimus-eluting coronary stent. The lesions are of average length in average-sized vessels ("workhorse"). A companion sub-trial evaluates outcomes in smaller vessels (SV) and another sub-trial evaluates outcomes in longer lesions (LL).

Timeline

Start
2009-01
Primary completion
2010-09
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Background Aspirin Small molecule 75 mg —
Background Aspirin Small molecule 162 mg —
Background Aspirin Small molecule 325 mg —
Background Clopidogrel Small molecule 75 mg —
Background Prasugrel Small molecule — —
Background ticlopidine Small molecule 250 mg —